Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of PU-AD in Healthy Subjects
NCT03935568Phase 1Terminated
- Sponsor
- Samus Therapeutics
- Start
- Jun 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Icapamespib in Alzheimer's disease (AD) (5 cohorts), sponsored by Samus Therapeutics. Primary endpoint: Safety and Tolerability of Single and Multiple Doses. Started Jun 2019; status: terminated.
02
Drugs
Icapamespib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03935568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03935568.